---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-011416"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2023-03-31T23:59:59+00:00"
generated_at: "2026-06-17T07:55:01.714625+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Atara CFO Utpal Koppikar resigns effective March 31; enters six-month consulting agreement

## Summary
- Utpal Koppikar resigned as CFO effective March 31, 2023, and entered a six-month consulting agreement.
- Consulting fee: $2,800/month for up to a specified number of hours, plus $175/hour for excess hours.
- Outstanding equity awards will continue to vest during the consulting term.
- No successor named in the filing; search for new CFO is presumably ongoing.

## SEC filing metadata
- accession: 0000950170-23-011416
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2023-03-31T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017023011416/0000950170-23-011416-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017023011416/atra-20230331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-011416
- JSON: https://secwatch.observer/filing/0000950170-23-011416.json
- Plain text: https://secwatch.observer/filing/0000950170-23-011416.txt

## Key facts
- Executive change
  Utpal Koppikar resigned as Executive Vice President, Chief Financial Officer at Atara Biotherapeutics, Inc..
  - Action: resigned
  - Role: Executive Vice President, Chief Financial Officer
  source text: On February 3, 2023, Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), announced that Utpal Koppikar, the Company’s Executive Vice President, Chief Financial Officer, notified the Company of his intention to resign from the Company effective as of March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017023011416/0000950170-23-011416-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.